Heart failure especially with preserved ejection fraction is much more common in women with obesity or diabetes compared to their male counterparts [80]; thus, SGLT2 inhibitors can clearly reduce disease burden and improve quality of life particularly in older women. This evidence concerns the gene SLC5A2 and heart failure.